Quantitative MRI can detect subclinical disease progression in muscular dystrophy by Fischmann, Arne et al.
ORIGINAL COMMUNICATION
Quantitative MRI can detect subclinical disease progression
in muscular dystrophy
Arne Fischmann • Patricia Hafner •
Susanne Fasler • Monika Gloor • Oliver Bieri •
Ueli Studler • Dirk Fischer
Received: 14 August 2011 / Revised: 21 December 2011 / Accepted: 21 December 2011 / Published online: 2 February 2012
 Springer-Verlag 2012
Abstract Oculopharyngeal muscular dystrophy (OPMD)
is a rare autosomal dominant muscular dystrophy with late
onset and slow progression. The aim of this study was to
compare different methods of quantitative MRI in the
follow-up of OPMD to semiquantitative evaluation of MRI
images and to functional parameters. We examined
8 patients with genetically confirmed OPMD and 5 healthy
volunteers twice at an interval of 13 months. Motor func-
tion measurements (MFM) were assessed. Imaging at 1.5 T
(Siemens Magnetom Avanto) comprised two axial slice
groups at the largest diameter of thigh and calf and inclu-
ded T1w TSE, 2-point Dixon for muscular fat fraction
(MFF) and a multi-contrast TSE sequence to calculate
quantitative T2 values. T1 images were analyzed using
Fischer’s semiquantitative 5-point (0–4) scale. MFM and
visual scores showed no significant difference over the
study period. Overall T2 values increased in patients over
the study period from 49.4 to 51.6 ms, MFF increased from
19.2 to 20.7%. Neither T2 values nor MFF increased in
controls. Changes in T2 correlated with the time interval
between examinations (r2 = 0.42). In this small pilot trial,
it was shown that quantitative muscle MRI can detect
subclinical changes in patients with OPMD. Quantitative
MRI might, therefore, be a useful tool for monitoring
disease progression in future therapeutic trials.
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Introduction
Oculopharyngeal muscular dystrophy (OPMD) is a rare
autosomal dominant muscular dystrophy with late onset and
slow progression, caused by a repeat expansion in the
PABPN-1 (polyadenlyate binding protein-1) gene. Disease
prevalence worldwide is 1:100,000, but is much higher in
certain communities, e.g., French Canadians and Bukhara
Jews. Symptoms include initial ptosis and difficulties swal-
lowing as well as later proximal weakness [1]. We recently
showed that semiquantitative muscular magnetic resonance
imaging (MRI) correlates with clinical abilities [2].
Future trials in muscular dystrophies require validated
objective outcome measures. One main objective of the
international Treat-NMD-Network is to develop such
standardized protocols [3]. Unfortunately, even validated
clinical scales are influenced by fatigue, concentration,
cooperation, and limited inter- and intrarater repeatability.
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In contrast, objective and quantitative biomarkers to assess
the severity and progression of muscle degeneration are
still largely lacking, with quantitative MRI being a very
promising method. MRI has some important advantages: it
is noninvasive, time-sparing, includes all muscles of an
anatomic region and identical fat/water phantoms can be
used for calibration in different multicenter trial sites.
Multiple quantitative methods to evaluate muscular fat
content have been evaluated [4, 5]. But only a few trials
describe follow-up findings of MRI in neuromuscular dis-
orders [4, 6].
The aim of this study was to compare different objective
quantitative and semiquantitative MRI methods to vali-
dated clinical parameters in the follow-up of OPMD.
Materials and methods
Eight patients with genetically confirmed oculopharyngeal
muscular dystrophy were recruited (age 41–76 years, see
Table 1). All patients were heterozygous carriers of a
(GCN)13 allele with the exception of patient three who had
a (GCN)15 allele. The clinical data and initial MRI findings
were previously reported [2]. In addition, 5 healthy indi-
viduals (aged 28 ± 6 years) were examined twice at an
interval of 13 months to establish stability of quantitative
measurements. All measurements were approved by the
local ethics committee (EKBB No. 83/08) and all partici-
pants gave written informed consent.
Physical assessment was performed prior to imaging in
all but 2 patients, who did not wish to participate in this
part of the study, using the motor function measurement
(MFM) scale, performed by a physiotherapist trained in
MFM scoring. This scale evaluates standing position and
transfers, axial and proximal motor function as well as
distal motor function. Subset scores for each dimension and
a total score are expressed in percentage points. A healthy
volunteer achieves 100% in all dimensions, while a score
below 60% usually indicates loss of ambulation [7]. It has
been shown that this scale has a high interrater reliability,
does not require any special equipment, and is well toler-
ated by patients [8].
All imaging was performed on a 1.5-T scanner (Mag-
netom Avanto, Siemens, Erlangen, Germany) with a
16-element matrix leg angiography coil. Imaging parame-
ters were identical to the sequences reported in a previous
publication [5].
In short, two axial slice groups were centered at 14.5 cm
below and 17.5 cm above the knee joint, respectively, to
include the largest diameter of the thigh and the lower leg.
An imaging matrix of 384 9 384 and a field of view of
400 9 400 mm2 were used, resulting in a 1 mm in-plane
resolution with 3 mm slice thickness.
Imaging sequences included a standard T1-weighted
turbo spin echo (TSE) sequence (30 slices, TR = 457 ms,
TE = 7.5 ms) for anatomical reference and visual evalu-
ation of fatty replacement, three-dimensional (3D) gradient
echo sequence with two different echo times for in-phase
and opposed-phase imaging (3D, 30 slices, TR = 20 ms,
TE1 = 2.38, TE2 = 4.76 ms, flip angle = 25). T2 quan-
tification was based on a multicontrast TSE sequence (3
slices, TR = 1,330 ms, TE = 10, 20, 30, …, 320 ms—31
echoes). The entire protocol was completed within
20:44 min.
Table 1 Motor function measurements (MFM) and visual evaluation of fatty replacement for all patients. The youngest patient (patient 6)
presented without symptoms of OPMD
Patient
No
Age Age
at
onset
Sex Interval
between
scans
Initial
evaluation
MFM av (%)
Repeat
evaluation
MFM av (%)
Average
visual Reader
1 initial
Average
visual Reader
1 repeat
Average
visual Reader
2 initial
Average
visual Reader
2 repeat
1 75 40 F 11.2 97.9 99.0 0.31 0.36 1.10 1.10
2 69 45 M 12.2 84.4 83.3 2.52 2.52 2.47 2.47
3 59 49 F 12.2 96.9 99.0 1.05 1.05 1.32 1.32
4 61 55 F 16.3 91.7 92.8 2.0 2.0 1.42 1.42
5 63 50 F 16.3 93 96.9 1.05 1.0 2 2
6 41 n.a. M 16.3 100 100 0.25 0.21 1.25 1.25
7 54 – F 10.1 n.a. n.a. 0.47 0.47 1.79 1.79
8 69 50 F 8.5 n.a. n.a. 0.26 0.26 1.42 1.42
Mean 13.0 93.98 95.2 0.91 0.91 1.64 1.64
SD 5.63 6.3 0.78 0.78 0.50 0.50
Visual scores by reader 1 showed minimal differences (patients 1, 5, and 6) between initial and repeat scans. Reader 2 detected no differences
between initial and repeat scans
SD Standard deviation, n.a. not applicable
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Repeat imaging in patients was performed after an
average of 13 months (8.5–16.3 month), due to restricted
patient availability and a large recruitment area. All vol-
unteers were rescanned after 13 months (mean 13 months,
SD 0.1 months).
Two radiologists experienced in neuromuscular imag-
ing, blinded to clinical findings, evaluated the images as
previously described [2] using a visual 5-point scale [9].
Table 2 lists all the evaluated muscles. The mean fat
fraction (MFF) was calculated using a 2-point Dixon (2PD)
reconstruction method. T2 relaxation times were calculated
from a pixel-by-pixel mono-exponential least-squares fit to
the signal at echo times ranging from 20–320 ms as
described previously [5]. Calculations were made based on
regions of interest (ROI) encompassing the cross-sectional
area of the whole muscle on three slices, avoiding chemical
shift artifacts, as given by the T2 TSE sequence [5]. In
addition, ROI positioning was confirmed on the fat, water,
and T2 maps (see Fig. 1).
Imaging scores and T2 values were analyzed with
averaged values of both legs due to symmetrical
involvement. Arithmetic mean of the visual scores from
the thigh, lower leg, and whole leg were calculated and
compared to clinical assessment given by the MFM scale.
Mean MFF from 2PD and mean T2 values of each ROI
were averaged across both legs and across the three slices
given by the T2-weighted images [5]. Differences
between initial and follow-up images were compared
using a two-sided t test. Correlations of quantitative fat
content, clinical and MRI scores as well as correlations
with age and interval between imaging were calculated as
Spearman’s rank coefficient with JMP 8.0.2 (SAS Insti-
tute, Cary, NC, USA).
Results
Follow-up average MFM scores showed no significant
difference (p = 0.18) of functional abilities compared to
the initial examination (see Table 1). Examples of fatty
replacement are shown in Fig. 2. MFM scores decreased
with increasing fat fraction (r = -0.98/-0.92 for initial/
repeat) and with increasing fatty replacement on visual
evaluation (r = -0.98 for initial and repeat), as well as
with increasing T2 values (r = -0.94/-0.90 for initial/
repeat) (see additional online material E1). This negative
correlation was significant for all analyses (p \ 0.01).
Semiquantitative visual scores showed no relevant
change over the study period with an average change per
patient of 0.0 (-0.05 to 0.05). When visual changes were
observed, these were limited to a maximum of one muscle
per patient.
Table 2 Quantitative T2
measurements and MFF over all
patients per muscle
p is given for the two-sided t test
* Significance at a 95% level
Muscle T2 (in ms)
initial
T2 (in ms)
follow-up
p Fat fraction
(in %) initial
Fat fraction
(in %) follow up
p
Rectus femoris 31.8 32.1 0.76 7.4 6.1 0.9
Vastus intermedius 41.9 43.8 0.11 13.4 14.6 0.18
Vastus lateralis 36.6 37.3 0.34 9.1 9.2 0.8
Vastus medialis 40.1 41.5 0.07 10.2 11.1 0.24
Long biceps 56.3 58.8 0.05 27.5 31.0 0.01*
Short biceps 46.7 49.1 0.06 19.7 21.4 0.10
Semimembranosus 58.7 61.1 \0.01* 30.6 32.9 \0.01*
Semitendinosus 50.2 52.7 0.04* 24.2 26.1 0.07
Adductor magnus 71.7 77.8 \0.01* 42.8 46.9 0.01*
Gracilis 35.8 38.2 0.07 11.8 11.7 0.59
Sartorius 43.1 45.8 0.10 16.4 17.8 0.35
Anterior tibial 43.8 45.8 0.14 9.8 11.6 0.04*
Digital extensor 53.3 56.1 \0.01* 18.4 20.4 0.04*
Peroneus 54.0 55.9 0.05 21.2 22.1 0.38
Posterior tibial 50.8 52.0 0.18 15.3 17.6 0.04*
Soleus 64.9 66.6 0.12 29.2 32.2 0.02*
Medial gastroc 56.3 57.4 0.44 22.3 22.4 0.90
Lateral gastroc 53.2 57.0 0.15 15.6 18.3 0.17
Mean thigh 46.6 48.9 \0.001* 19.4 20.8 \0.001*
Mean calf 53.7 55.8 \0.001* 18.8 20.6 \0.001*
Mean all muscles 49.4 51.6 \0.001* 19.2 20.7 \0.001*
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Quantitative measurements showed a significant
increase of T2 times and MFF for all patients (Table 2).
Controls showed no significant change: T2 was 35.3 ms
(SD 3.83) and 35.2 ms (SD 4.01 ms) at the initial and
repeat examinations, respectively (p = 0.44), while the
corresponding fat fractions were 7.8 (SD 2.6%) and 7.2%
(SD 2.2%) for initial and repeat examinations (p = 0.11).
T2 values in patients were significantly higher compared to
controls (p \ 0.0001) and the change over time was sig-
nificantly higher in patients (p = 0.01) when averaged over
all muscles and patients (Fig. 3). However, this was not
necessarily the case for each individual subject and muscle
(Fig. 4 and Figure E2). Moreover, the change in T2 in
patients increased in patients for longer interval between
examinations (r = 0.71, see Fig. 5).
When averaged over functional–anatomical muscle
groups, T2 values in the thigh changed more prominently
across the hamstrings (T2 difference ?3.07 ms,
p \ 0.0001) as compared to the quadriceps (T2 difference
?0.96 ms, p = 0.04), whereas in the calf, changes in the
flexors (soleus and gastrocnemius) were more prominent
(T2 difference ?4.0 ms) as compared to the extensors
(tibialis anterior, extensor digitorum and hallucis longus,
peroneus longus) (T2 difference ?1.55 ms). T2 times
increased in all muscles, while MFF showed more heter-
ogeneous results and even a decrease in the rectus femoris
and gracilis (Table 2). MFF strongly correlated with T2
times with r2 of -0.98 and -0.96 at initial scan and fol-
low-up, respectively.
Discussion
In this study, it has been demonstrated that T2 and MFF
quantification could be used to detect subclinical changes
in slowly progressive muscular dystrophies such as OMPD.
While clinical data and visual analysis of fat content were
stable, quantitative measurements, especially T2 measure-
ments showed a constant increase over the study period.
This is in accordance with the known history of the disease,
Fig. 1 Typical fat fraction
maps (a, b) and T2 maps (c,
d) of the right thigh. ROIs (a,
c) superimposed on the images
with annotations for the muscle
groups examined. The
hamstrings are shaded in blue,
while the quadriceps femoris is
shaded in red. AM adductor
magnus, BB biceps femoris
short head, BL biceps femoris
long head, GR gracilis, RF
rectus femoris, SA sartorius, SM
semimembranosus, ST
semitendinosus, VI vastus
intermedius, VL vastus lateralis,
VM vastus medialis
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which is dominated by a very slow progression over long
intervals [1], with expected changes in MFM only after an
interval of several years. All muscles showed an increase in
T2 times, although differences were small, while differ-
ences in MFF were more heterogeneous, indicating that T2
might be more sensitive to slow changes. Even the pre-
symptomatic patient with a known mutation of the PAB-
PN-1 gene had normal MFM scores and no visual signs of
fatty infiltration, while T2 times and MFF significantly
increased over the study period (Fig. 4). This indicates that
MRI might be used for monitoring presymptomatic
patients, although evidence is currently limited. Whether
MRI could also serve as an objective outcome for the
assessment in future therapeutic trials needs to be evaluated
in future trials with larger cohorts of patients with geneti-
cally confirmed OPMD, preferably including groups of
younger presymptomatic patients.
Similar to trials in myotonic dystrophy [10] or inclusion
body myositis [11], we found a correlation of MRI with
functional parameters but not with patient age or disease
duration. Kim et al. [4] examined children with Duchenne
muscular dystrophy and found increasing T2 times in
5 patients and decrease in 2 patients after steroid therapy.
Bryan et al. [12] found that T2 times correlated with
muscle action potential amplitude in patients with ALS.
Both studies were in patients with rapidly progressive
diseases, while we could show for the first time the use of
quantitative follow-up MRI studies in adult muscular
dystrophies with slower progression.
Fig. 2 Images of the thighs (a, b) from a patient with more advanced
involvement of the hamstrings (patient 2) and images from the calves
(c, d) of a different patient (patient 3) with moderate involvement
predominantly in the soleus. b and d are from the initial scan, a and
c from the follow-up study: no difference in the amount of fatty
replacement is visible on the scans. Example evaluations by reader
1/2 for the right leg were the following: rectus femoris = 0/1, vastus
lateralis = 1/2, vastus intermedius = 3/3, vastus medialis = 1/2,
gracilis = 0/1, sartorius = 0/1, semimembranosus = 3/3, semitendi-
nosus = 3/3, short biceps = 2/2, long biceps = 3/3, tibialis ante-
rior = 1/2, peroneus = 1/2, tibialis posterior = 1/2, soleus = 2/2,
gastrocnemius lateralis = 1/2, gastrocnemius medialis = 1/2
Fig. 3 Comparison of T2 values and MFF between patients and
controls on a muscle-by-muscle basis. Red lines indicate mean values,
standard deviations, and standard deviations of means
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Our study has limitations, such as the small number of
OPMD patients. We pre-specified statistical evaluations as
differences in MFM, T2 and fat fraction between initial and
repeat exams; these were highly specific. The evaluation of
the single muscles in Table 2 was performed to estimate
whether specific muscles showed greater changes. The
latter evaluations were, however, not corrected for multiple
comparisons, p values should, therefore, only be regarded
as indications of the direction and size of change.
Another limitation was in the lack of a gold standard for
the assessment of the fat infiltration, although MFF on MRI
showed excellent agreement to histopathologic results in
patients with muscular dystrophy [13]. While fat mea-
surements on muscle biopsy are currently regarded to be
the gold standard [14], we were not able to make such
correlations by repeated muscle biopsies for ethical rea-
sons. In spectroscopic studies, T2 relaxation measurements
correlated with fat content [15]. However, exercise can
increase the water content in the intracellular space, which
might influence T2 values [16]. The latter might also be the
underlying cause of the variation in T2 values in one vol-
unteer with stable MFF. Furthermore the refusal of
2 patients to participate in MFM evaluation might intro-
duce bias into the clinical correlations.
Another potential limitation lies in potential confound-
ing effects of the 2-point Dixon method. We used an
implementation for the 2-point Dixon technique, which
accounts for phase errors from magnetic field inhomoge-
neities. A potential issue of gradient echo based 2-point
Dixon imaging is that T1 and T2* relaxation may cause
inaccurate fat and water images [17]. This leads to an
overestimation of low MFF and an underestimation of high
MFF by the 2-point Dixon method. The 3-point Dixon
technique, which is less susceptible to inaccuracies, was
not available on Siemens scanners at the time of this study.
We also tested other methods of fat quantifications and
found them to be less stable compared to the 2-point Dixon
method [5]. A determination of absolute T2 values might
also be problematic. The apparent T2 of lipid protons in
Fig. 4 Comparison of quantitative MRI parameters between patients
(1–8 in blue) and controls (c1–c5 in red) plotted as difference
between scans per muscle. Green lines indicate mean values ± one
standard deviation. In patients, fat fraction and T2 values increased in
comparison to controls. However, this was not true for all patients or
all muscles
Fig. 5 Changes in T2 values and MFF over time in correlation with
scanning interval. The trend line demonstrates the increase in T2 with
increasing interval
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fast spin-echo MRI is increased [18]. Furthermore, the
assumption of a single mono-exponential decay is an
oversimplification in the presence of fat [15].
However, these potential issues in 2-point Dixon and T2
imaging have no significant impact on the study outcome,
as the main interest was not directed toward absolute val-
ues, but rather toward a variation of parameters with dis-
ease progression. The latter were verified by the stable
results in volunteers over the study period.
In conclusion, we found that quantitative MRI is a
sensitive method for the detection of subclinical changes in
OPMD: quantitative changes over time can be detected,
which do not appear on conventional imaging or in func-
tional measurements like the MFM over the same period.
Thus, quantitative MRI might be used as an additional
objective tool in the surveillance of progression in mus-
cular dystrophy, but larger trials in OPMD as well as in
different muscle diseases need to be performed to verify
and validate this finding.
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